About InterMune (NASDAQ:ITMN)
InterMune, Inc. (InterMune) is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases. Pulmonology is the field of medicine concerned with the diagnosis and treatment of lung conditions. The Company has a product in pulmonology, pirfenidone, which is an orally active, small molecule compound. On January 2, 2013, it began the commercial launch of Esbriet in Canada. IPF is a disease characterized by progressive scarring, or fibrosis, of the lungs, which leads to their deterioration and destruction. The prognosis is poor for patients with IPF, which occurs primarily in persons 40 to 70 years old with a median survival time from diagnosis of two to five years. Pirfenidone in Japan is sold by Shionogi under the brand name Pirespa. Pirfenidone in India is sold by Cipla Ltd. under the brand name Pirfenex, and in China is sold by Shanghai Genomics. In September 2014, Roche Holding AG acquired InterMune.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:ITMN
- CUSIP: 45884X10
- Web: N/A
- 200 Day Moving Avg: $68.00
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -55.56
- P/E Growth: 0
Frequently Asked Questions for InterMune (NASDAQ:ITMN)
What is InterMune's stock symbol?
InterMune trades on the NASDAQ under the ticker symbol "ITMN."
Who are some of InterMune's key competitors?
Some companies that are related to InterMune include Grifols, S.A. (GRFS), Jazz Pharmaceuticals PLC (JAZZ), ProMetic Life Sciences (PLI), Theratechnologies (TH), Mirati Therapeutics (MRTX), SIGA Technologies (SIGA), Anavex Life Sciences Corp. (AVXL), XOMA Corporation (XOMA), VBI Vaccines (VBIV), Osiris Therapeutics (OSIR), ContraFect Corporation (CFRX), Protalix Biotherapeutics (PLX), Concordia International Corp (CXR), Trillium Therapeutics (TRIL), Aevi Genomic Medicine (GNMX), Ohr Pharmaceuticals (OHRP), Can Fite Biopharma Ltd (CANF) and Can Fite Biopharma Ltd (CANF).
How do I buy InterMune stock?
Shares of InterMune can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is InterMune's stock price today?
MarketBeat Community Rating for InterMune (NASDAQ ITMN)MarketBeat's community ratings are surveys of what our community members think about InterMune and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of InterMune stock can currently be purchased for approximately $73.89.
Consensus Ratings for InterMune (NASDAQ:ITMN) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|Consensus Price Target History for InterMune (NASDAQ:ITMN)
Analysts' Ratings History for InterMune (NASDAQ:ITMN)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for InterMune (NASDAQ:ITMN)Earnings History by Quarter for InterMune (NASDAQ ITMN)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/6/2014||Q214||($0.56)||($0.72)||$33.96 million||$35.70 million||View||Listen|
|5/1/2014||Q114||($0.62)||($0.59)||$28.24 million||$30.30 million||View||Listen|
|7/24/2013||Q2 2013||($0.70)||($0.77)||$12.95 million||$14.40 million||View||Listen|
|4/24/2013||Q1 2013||($0.73)||($0.64)||$10.53 million||$10.53 million||View||Listen|
|2/21/2013||Q4 2012||($0.87)||($0.90)||$8.31 million||$8.20 million||View||Listen|
|11/7/2012||Q312||($0.83)||($0.70)||$6.31 million||$7.50 million||View||N/A|
Earnings Estimates for InterMune (NASDAQ:ITMN)
Current Year EPS Consensus Estimate: $-2.74 EPS
Next Year EPS Consensus Estimate: $-1.33 EPS
Dividend History for InterMune (NASDAQ:ITMN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for InterMune (NASDAQ:ITMN)Insider Trades by Quarter for InterMune (NASDAQ:ITMN)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|9/2/2014||Andrew Kenneth William Powell||EVP||Sell||7,500||$73.47||$551,025.00|| |
|8/13/2014||Paul D Arata||EVP||Sell||7,500||$50.00||$375,000.00|| |
|8/11/2014||John Hodgman||CFO||Sell||4,724||$43.05||$203,368.20|| |
|8/7/2014||Daniel G Welch||CEO||Sell||171,025||$44.98||$7,692,704.50|| |
|7/17/2014||Paul D Arata||EVP||Sell||2,382||$41.00||$97,662.00|| |
|7/15/2014||Jonathan A Leff||EVP||Sell||35,000||$43.08||$1,507,800.00|| |
|6/18/2014||Sean P Nolan||EVP||Sell||10,000||$47.10||$471,000.00|| |
|6/16/2014||Daniel G Welch||CEO||Sell||15,000||$45.02||$675,300.00|| |
|6/13/2014||Sean P Nolan||EVP||Sell||20,000||$42.80||$856,000.00|| |
|6/4/2014||Daniel G Welch||CEO||Sell||3,914||$39.19||$153,389.66|| |
|6/3/2014||John Hodgman||CFO||Sell||1,201||$38.78||$46,574.78|| |
|6/3/2014||Jonathan A Leff||EVP||Sell||1,153||$38.78||$44,713.34|| |
|5/30/2014||Daniel G Welch||CEO||Sell||4,565||$40.06||$182,873.90|| |
|5/29/2014||David S Kabakoff||Director||Sell||5,000||$39.56||$197,800.00|| |
|5/27/2014||Daniel G Welch||CEO||Sell||41,493||$40.03||$1,660,964.79|| |
|5/19/2014||Sean Nolan||EVP||Sell||7,500||$39.50||$296,250.00|| |
|5/8/2014||Sean Nolan||VP||Sell||2,644||$35.85||$94,787.40|| |
|5/6/2014||Daniel Welch||CEO||Sell||60,432||$34.76||$2,100,616.32|| |
|3/4/2014||Jonathan Leff||EVP||Sell||27,361||$30.95||$846,822.95|| |
|3/4/2014||Nepi Giacomo Di||Director||Sell||70,000||$30.84||$2,158,800.00|| |
|1/10/2014||Daniel Welch||CEO||Sell||50,000||$17.00||$850,000.00|| |
|12/2/2013||Daniel Welch||CEO||Sell||20,000||$13.99||$279,800.00|| |
|10/1/2013||Daniel G Welch||CEO||Sell||70,000||$15.43||$1,080,100.00|| |
|8/30/2013||David Kabakoff||Director||Sell||10,002||$14.82||$148,229.64|| |
|8/27/2013||Angus Russell||Director||Buy||6,600||$14.53||$95,898.00|| |
Headline Trends for InterMune (NASDAQ:ITMN)
Latest Headlines for InterMune (NASDAQ:ITMN)
InterMune (ITMN) Chart for Tuesday, October, 17, 2017